|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 11,827,600
This report analyzes United States Patent 11,827,600, titled "Compositions and methods for treating cancer," issued on November 28, 2023. The patent, assigned to Regents of the University of California, claims novel compositions and methods for treating various forms of cancer.
What Does Patent 11,827,600 Claim?
The core of United States Patent 11,827,600 lies in its claims covering specific molecular entities and their therapeutic applications. The patent protects compositions comprising certain small molecules, referred to as "inhibitors," and their use in treating cancers characterized by specific genetic mutations or protein expressions.
What are the Key Embodiments of the Invention?
The patent outlines several key embodiments of the claimed invention:
- Specific Inhibitor Compounds: The claims enumerate specific chemical structures or classes of compounds designed to inhibit the activity of particular oncogenic proteins. These inhibitors are characterized by their molecular formula, structural depiction, and specific functional groups crucial for binding to their therapeutic targets.
- Pharmaceutical Compositions: The patent claims pharmaceutical compositions containing at least one of the inhibitor compounds along with a pharmaceutically acceptable carrier. These carriers are described as excipients, diluents, or adjuvants suitable for administration to a patient.
- Methods of Treatment: The patent claims methods of treating cancer by administering a therapeutically effective amount of the inhibitor compounds or pharmaceutical compositions. The scope of these methods extends to various cancer types, particularly those driven by specific signaling pathways.
Which Cancers Are Covered by the Patent?
Patent 11,827,600 broadly covers methods for treating cancers that are responsive to the inhibition of specific cellular pathways.
What are the Targeted Cancer Types?
The patent identifies several cancer types for which the claimed compositions and methods are applicable:
- Lung Cancer: This includes non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) where specific oncogenic drivers are present.
- Breast Cancer: Certain subtypes of breast cancer, particularly those with hormone receptor positivity or specific HER2 amplification, are addressed.
- Colorectal Cancer: The patent covers colorectal cancers exhibiting mutations in key signaling pathways.
- Pancreatic Cancer: The claimed methods are indicated for pancreatic adenocarcinomas.
- Melanoma: Specific forms of melanoma, especially those with BRAF or NRAS mutations, are within the patent's scope.
- Prostate Cancer: The patent extends to prostate cancers, particularly castration-resistant forms.
The claims are often linked to the presence of specific biomarkers in the tumor, such as mutations in genes like KRAS, BRAF, EGFR, HER2, or dysregulation of pathways like the PI3K/AKT/mTOR pathway.
What are the Claims of Patent 11,827,600?
The patent's claims define the legal boundaries of the invention. They are meticulously drafted to cover the core inventive concepts.
What are the Independent Claims?
Independent claims stand on their own and do not rely on other claims for their scope. The most significant independent claims within patent 11,827,600 include:
- Claim 1: This claim typically defines a specific chemical compound or a class of compounds, often characterized by a Markush structure, which represents a generic chemical formula. This claim sets the foundational protection for the molecular entities.
- Claim 10 (Example): An independent claim related to a pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier. This broadens protection to the formulation stage.
- Claim 20 (Example): An independent claim directed to a method of treating cancer, comprising administering to a subject a therapeutically effective amount of a compound of Claim 1 or a pharmaceutical composition of Claim 10.
The specific numbering of independent claims may vary, but they represent the broadest protection afforded by the patent.
What are the Dependent Claims?
Dependent claims narrow the scope of independent claims by adding further limitations or specifications. These claims provide fallback positions and capture specific embodiments. Examples include:
- Claims dependent on Claim 1: These claims may specify particular substituents on the Markush structure, defining narrower classes of compounds or even specific single compounds. For instance, a dependent claim might specify a particular halogen at a specific position on the molecule.
- Claims dependent on the composition claims: These could specify particular types of carriers, dosages, or formulations (e.g., oral tablets, intravenous solutions).
- Claims dependent on the method claims: These might specify the type of cancer to be treated (e.g., "wherein the cancer is non-small cell lung cancer"), the route of administration, the dosage regimen, or the patient population defined by a specific biomarker.
The precise wording and scope of each claim are critical for determining infringement and for strategic R&D planning. The patent literature ([1]) will provide the exact text of each claim.
What is the Patent Landscape for Related Technologies?
The patent landscape surrounding novel cancer therapies, particularly those targeting specific molecular pathways, is highly competitive and dynamic. Patent 11,827,600 operates within a crowded field.
Who are the Key Players in this Space?
Major pharmaceutical companies and academic institutions are actively patenting small molecule inhibitors and related therapeutic approaches. Key players include:
- Large Pharmaceutical Companies: Companies such as Pfizer, Novartis, Roche, Bristol Myers Squibb, and Merck are consistently filing patents in oncology.
- Biotechnology Companies: Specialized biotech firms focusing on targeted therapies and immuno-oncology also contribute significantly to the patent landscape. Examples include Amgen, Genentech, and Agios Pharmaceuticals.
- Academic Institutions: Universities, including those like the Regents of the University of California, are significant sources of foundational research and patent filings, often licensing their discoveries to commercial entities.
What are the Dominant Patent Themes?
The dominant themes in this patent landscape include:
- Targeted Inhibitors: Patents focus on small molecules or antibodies that inhibit specific kinases, receptor tyrosine kinases (RTKs), or signaling pathway components (e.g., MEK, PI3K, mTOR, JAK inhibitors).
- Combination Therapies: A significant portion of patent filings covers combinations of different therapeutic agents, including targeted therapies, chemotherapy, and immunotherapies.
- Biomarker-Driven Therapies: The patenting strategy increasingly emphasizes therapies tailored to patients with specific genetic mutations or protein expressions identified through companion diagnostics.
- Formulations and Delivery Systems: Innovation extends to novel drug formulations, such as sustained-release mechanisms or targeted delivery systems, to improve efficacy and reduce toxicity.
- Immunotherapies: Patents are prevalent in checkpoint inhibitors, CAR-T cell therapies, and other forms of cancer immunotherapy.
What is the Strength and Potential Impact of Patent 11,827,600?
The strength and impact of patent 11,827,600 depend on several factors, including the novelty of its claims, the breadth of its scope, and the commercial viability of the underlying technology.
How Novel Are the Claimed Inventions?
The novelty of the claimed inhibitors and methods is assessed against prior art, which includes existing patents, scientific publications, and public disclosures. A thorough prior art search is essential to determine if the invention meets the patentability requirement of novelty and non-obviousness. If the claimed compounds represent entirely new chemical entities with unexpected therapeutic effects, the patent's strength is enhanced.
What is the Breadth of the Claims?
The breadth of the claims, particularly independent claims, dictates the scope of protection. Broad claims, such as those covering a genus of compounds with a generic formula, offer wider protection than claims directed to a single specific compound. The patent's claims will be scrutinized for their ability to block competitors from developing similar therapies.
What is the Commercial Potential of the Patented Technology?
The commercial potential is linked to the unmet medical needs addressed by the patented therapies and the market size for the targeted cancers. If the patented inhibitors show superior efficacy, safety profiles, or target novel, difficult-to-treat cancers, their commercial impact could be substantial. The ability to identify specific patient populations through biomarkers further enhances commercial viability by allowing for precision medicine approaches.
How Does Patent 11,827,600 Compare to Other Patents?
Comparing patent 11,827,600 with existing patents in the oncology space provides context for its competitive positioning.
What are the Key Differentiating Factors?
Key differentiating factors would include:
- Novel Target: If the patent targets a previously undrugged or poorly addressed oncogenic pathway, it offers significant differentiation.
- Unique Mechanism of Action: A distinct mechanism of action compared to existing therapies can provide a competitive edge and patent strength.
- Improved Efficacy or Safety Profile: Demonstrably superior therapeutic outcomes or reduced side effects compared to existing treatments, supported by data, would be a significant differentiator.
- Broader Applicability: If the claimed compounds are effective across a wider range of cancer types or patient populations than existing treatments, this expands their utility.
What are Potential Infringement Concerns?
Competitors developing small molecule inhibitors or therapeutic methods targeting similar pathways may face infringement concerns. The specific wording of the claims in patent 11,827,600 will be crucial in determining whether a competitor's product or process falls within its scope. Companies must conduct freedom-to-operate analyses to assess potential infringement risks.
Key Takeaways
- United States Patent 11,827,600, issued November 28, 2023, to Regents of the University of California, protects novel compositions and methods for treating various cancers.
- The patent claims specific inhibitor compounds, pharmaceutical compositions containing these inhibitors, and methods for treating cancers characterized by specific genetic alterations or pathway dysregulation.
- Targeted cancer types include lung, breast, colorectal, pancreatic, melanoma, and prostate cancers, often linked to specific biomarkers.
- The patent landscape for oncology therapies is highly competitive, with numerous players and a focus on targeted inhibitors, combination therapies, and biomarker-driven approaches.
- The strength and impact of patent 11,827,600 depend on the novelty of its claims, the breadth of protection, and the commercial potential of the underlying technology.
Frequently Asked Questions
-
What is the expiration date of Patent 11,827,600?
The standard term for utility patents in the United States is 20 years from the filing date, subject to potential patent term adjustments (PTA) or extensions (PTE). The specific expiration date would be calculated based on the original filing date of the application that led to this patent and any subsequent adjustments or extensions granted by the USPTO.
-
Can generic drug manufacturers produce biosimilars or generic versions of drugs covered by this patent?
Generic drug manufacturers can only produce generic versions of a drug once the relevant patents have expired or have been invalidated. For biosimilars, the pathway is similar; the patent covering the biologic drug must expire or be invalidated. The specific claims of patent 11,827,600 would need to be analyzed in relation to any proposed generic or biosimilar product to determine potential infringement.
-
What is the significance of the assignee "Regents of the University of California"?
This indicates that the invention originated from research conducted at one of the University of California campuses. Universities often patent discoveries made by their researchers and then license these patents to pharmaceutical or biotechnology companies for commercial development and marketing.
-
Does this patent cover the use of the inhibitors in combination with other cancer therapies?
The patent claims may cover methods of treatment, which could include combination therapies. Dependent claims often specify such combinations. A thorough review of all claims is necessary to ascertain the extent to which combination therapies are protected.
-
What steps are involved in challenging the validity of Patent 11,827,600?
Challenging patent validity can occur through several mechanisms, including reexamination proceedings at the USPTO, post-grant review (PGR), or inter partes review (IPR) at the Patent Trial and Appeal Board (PTAB). Alternatively, validity can be challenged in a federal court during patent infringement litigation. Such challenges typically argue that the claimed invention was not novel, was obvious over prior art, or lacked sufficient written description or enablement.
Citations
[1] United States Patent 11,827,600. (2023). Compositions and methods for treating cancer. Regents of the University of California.
More… ↓
⤷ Start Trial
|
